Mansour R, Shaker A, Abulsoud A, Mageed S, Ashraf A, Elsakka E
Mol Neurobiol. 2025; .
PMID: 40009259
DOI: 10.1007/s12035-025-04750-7.
Utpal B, Roy S, Zehravi M, Sweilam S, Raja A, Akiful Haque M
Animal Model Exp Med. 2025; 8(2):266-286.
PMID: 39808166
PMC: 11871115.
DOI: 10.1002/ame2.12525.
Zhang S, Yang Y, Lv X, Zhou X, Zhao W, Meng L
Brain Sci. 2024; 14(11).
PMID: 39595812
PMC: 11591915.
DOI: 10.3390/brainsci14111049.
Son G, Na Y, Kim Y, Son J, Clemenson G, Schafer S
Commun Biol. 2024; 7(1):1393.
PMID: 39455851
PMC: 11511827.
DOI: 10.1038/s42003-024-07089-2.
Zanirati G, Dos Santos P, Alcara A, Bruzzo F, Ghilardi I, Wietholter V
Int J Mol Sci. 2024; 25(13).
PMID: 39000479
PMC: 11242541.
DOI: 10.3390/ijms25137371.
Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson's disease and synucleinopathies.
Meccariello R, Carlo Bellenchi G, Pulcrano S, DAddario S, Tafuri D, Mercuri N
Front Cell Neurosci. 2024; 17:1328269.
PMID: 38249528
PMC: 10796818.
DOI: 10.3389/fncel.2023.1328269.
Current progression in application of extracellular vesicles in central nervous system diseases.
Zhang X, Huang J, Ni X, Zhu H, Huang Z, Ding S
Eur J Med Res. 2024; 29(1):15.
PMID: 38173021
PMC: 10763486.
DOI: 10.1186/s40001-023-01606-5.
Shared Molecular Pathways in Glaucoma and Other Neurodegenerative Diseases: Insights from RNA-Seq Analysis and miRNA Regulation for Promising Therapeutic Avenues.
Moreira Vasconcelos C, Ribas V, Petrs-Silva H
Cells. 2023; 12(17).
PMID: 37681887
PMC: 10486375.
DOI: 10.3390/cells12172155.
Brain-Derived Neurotrophic Factor Dysregulation as an Essential Pathological Feature in Huntington's Disease: Mechanisms and Potential Therapeutics.
Speidell A, Bin Abid N, Yano H
Biomedicines. 2023; 11(8).
PMID: 37626771
PMC: 10452871.
DOI: 10.3390/biomedicines11082275.
WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective.
Ramakrishna K, Nalla L, Naresh D, Venkateswarlu K, Viswanadh M, Nalluri B
Diseases. 2023; 11(3).
PMID: 37489441
PMC: 10366863.
DOI: 10.3390/diseases11030089.
Repressor Element-1 Binding Transcription Factor (REST) as a Possible Epigenetic Regulator of Neurodegeneration and MicroRNA-Based Therapeutic Strategies.
Nassar A, Satarker S, Gurram P, Upadhya D, Fayaz S, Nampoothiri M
Mol Neurobiol. 2023; 60(10):5557-5577.
PMID: 37326903
PMC: 10471693.
DOI: 10.1007/s12035-023-03437-1.
DNA double-strand break-free CRISPR interference delays Huntington's disease progression in mice.
Seo J, Shin J, Lee J, Kim D, Hwang H, Nam B
Commun Biol. 2023; 6(1):466.
PMID: 37117485
PMC: 10147674.
DOI: 10.1038/s42003-023-04829-8.
Mitochondria in Huntington's disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies.
Jurcau A, Jurcau C
Neural Regen Res. 2022; 18(7):1472-1477.
PMID: 36571344
PMC: 10075114.
DOI: 10.4103/1673-5374.360289.
The emerging role of long non-coding RNAs, microRNAs, and an accelerated epigenetic age in Huntington's disease.
Ghafouri-Fard S, Khoshbakht T, Hussen B, Taheri M, Ebrahimzadeh K, Noroozi R
Front Aging Neurosci. 2022; 14:987174.
PMID: 36185471
PMC: 9520620.
DOI: 10.3389/fnagi.2022.987174.
MicroRNAs in Learning and Memory and Their Impact on Alzheimer's Disease.
Wang I, Ho P, Tsai K
Biomedicines. 2022; 10(8).
PMID: 36009403
PMC: 9405363.
DOI: 10.3390/biomedicines10081856.
A Review of Molecular Interplay between Neurotrophins and miRNAs in Neuropsychological Disorders.
Abdolahi S, Zare-Chahoki A, Noorbakhsh F, Gorji A
Mol Neurobiol. 2022; 59(10):6260-6280.
PMID: 35916975
PMC: 9463196.
DOI: 10.1007/s12035-022-02966-5.
MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.
Nguyen T, Kumar M, Fedele E, Bonanno G, Bonifacino T
Int J Mol Sci. 2022; 23(9).
PMID: 35563107
PMC: 9104163.
DOI: 10.3390/ijms23094718.
Interplay of SOX transcription factors and microRNAs in the brain under physiological and pathological conditions.
Stevanovic M, Stanisavljevic Ninkovic D, Mojsin M, Drakulic D, Schwirtlich M
Neural Regen Res. 2022; 17(11):2325-2334.
PMID: 35535866
PMC: 9120710.
DOI: 10.4103/1673-5374.338990.
Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.
Costa M, Maciel P
Cell Mol Life Sci. 2022; 79(5):274.
PMID: 35503478
PMC: 11071829.
DOI: 10.1007/s00018-022-04280-8.
Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington's disease.
Islam J, So K, Kc E, Moon H, Kim A, Hyun S
Stem Cell Res Ther. 2021; 12(1):585.
PMID: 34809707
PMC: 8607638.
DOI: 10.1186/s13287-021-02653-7.